Zyfine

Jump to

Cadila up 4% on EIR report from USFDA for Ahmedabad SEZ unit

"Oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad has received an establishment inspection report (EIR) from the USFDA," the pharma company said in its filing.
Cadila rebounds but brokerages cut EPS forecast on USFDA warning

CLSA downgraded the stock to underperform from outperform with reduced target price at Rs 355 (from Rs 473 per share earlier). The brokerage also reduced US business estimates by 17/20 percent for FY17/18 that resulted in cutting EPS expectations by 19 percent for FY17/18.
No data integrity issue at Moraiya facility: Cadila Health

Pankaj R Patel, CMD, Cadila Healthcare, said there are no data integrity issues with the Moraiya facility. He said the company plans to give additional information to the US FDA to address the Moraiya issue

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Zyfine

Cadila up 4% on EIR report from USFDA for Ahmedabad SEZ unit

Cadila rebounds but brokerages cut EPS forecast on USFDA warning

No data integrity issue at Moraiya facility: Cadila Health